Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PV0J | ISIN: GB00BK71XP16 | Ticker-Symbol:
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
PEBBLE GROUP PLC Chart 1 Jahr
5-Tage-Chart
PEBBLE GROUP PLC 5-Tage-Chart
ACCESSWIRE
510 Leser
Artikel bewerten:
(2)

The Pebble Group PLC Announces Non-Executive Director and PDMR Share Dealings

Non-Executive Director and PDMR Share Dealings and Vesting of Long Term Incentive Plan (LTIP) Awards

MANCHESTER, UK / ACCESSWIRE / December 22, 2023 / The Pebble Group, a leading provider of digital commerce, products and related services to the global promotional products industry, announces that David Moss, Independent Non-Executive Director, purchased 100,000 Ordinary Shares of 1 pence each in the company ("Ordinary Shares") on 21 December 2023.

Following the purchase, David Moss has a beneficial interest in 100,000 Ordinary Shares representing 0.06% of the issued share capital of the Group.

The purchase of Ordinary Shares was from participants in The Pebble Group plc Long Term Incentive Plan ("LTIP"). Under the LTIP, on 21 December 2023, there was an exercise of 107,976 share options ("Options") and the vesting of 195,582 Conditional Share Awards.

Included in the participants of the Conditional Share Awards vesting was a PDMR who, concurrent with the vesting, also sold 67,043 Ordinary Shares.

Participant

Position

Ordinary Shares from Conditional Share Award

Ordinary Shares sold

Resultant holding in Ordinary Shares

% of issued share capital of the Group

Karl Whiteside

Group Managing Director, Brand Addition

67,043

67,043

853,820

0.51%

The exercise of nil cost Options and the vesting of Conditional Share Awards under the LTIP, including by one Group PDMR, has been satisfied through the allocation of existing Ordinary Shares of 1 pence each held by The Pebble Group Employee Benefit Trust ("EBT"). As such, no new Ordinary Shares have been issued in connection with the Option exercises or the Conditional Share Awards.

Following settlement of these transactions, the EBT will hold a total of 412,637 Ordinary Shares representing 0.25 per cent of the Group's total voting rights.

The notifications below, provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details.

Enquiries:

The Pebble Group
Chris Lee, Chief Executive Officer
Claire Thomson, Chief Financial Officer
+44 (0) 750 012 4121

Temple Bar Advisory (Financial PR)
Alex Child-Villiers/Sam Livingstone
+44 (0) 207 183 1190
pebble@templebaradvisory.com

Grant Thornton UK LLP (Nominated Adviser)
Samantha Harrison / Harrison Clarke / Ciara Donnelly
+44 (0) 207 184 4384

Berenberg (Corporate Broker)
Ben Wright / Marie Moy / Mollie D'Arcy Rice
+44 (0) 203 207 7800

About The Pebble Group plc-- www.thepebblegroup.com

The Pebble Group is a provider of digital commerce, products and related services to the global promotional products industry, comprising two differentiated businesses, Facilisgroup and Brand Addition, focused on specific areas of the promotional products market. For further information, please visit www.thepebblegroup.com.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

1

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

Karl Whiteside

2

Reason for the notification

(a)

Position/status

Group Managing Director, Brand Addition

(b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

The Pebble Group plc

(b)

LEI

213800LZUQAYBHDEQY04

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1 pence each

ISIN GB00BK71XP16

PEBB.L

(b)

Nature of the transaction

Vesting of Conditional share awards pursuant to The Pebble Group plc Long Term Incentive Plan

(c)

Price(s) and volume(s)

Price(s)

Volume(s)

1

NIL

67,043

(d)

Aggregated information

- Aggregated volume
- Price

N/A

(e)

Date of the transaction

21 December 2023

(f)

Place of the transaction

XLON

1

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

Karl Whiteside

2

Reason for the notification

(a)

Position/status

Group Managing Director, Brand Addition

(b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

The Pebble Group plc

(b)

LEI

213800LZUQAYBHDEQY04

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1 pence each

ISIN GB00BK71XP16

PEBB.L

(b)

Nature of the transaction

Sale of Ordinary Shares

(c)

Price(s) and volume(s)

Price(s)

Volume(s)

1

52.1p

67,043

(d)

Aggregated information

- Aggregated volume
- Price

N/A

(e)

Date of the transaction

21 December 2023

(f)

Place of the transaction

XLON

1

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

David Moss

2

Reason for the notification

(a)

Position/status

Independent Non Executive Director

(b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

The Pebble Group plc

(b)

LEI

213800LZUQAYBHDEQY04

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1 pence each

ISIN GB00BK71XP16

PEBB.L

(b)

Nature of the transaction

Purchase of Ordinary Shares from participants in The Pebble Group plc Long Term Incentive Plan

(c)

Price(s) and volume(s)

Price(s)

Volume(s)

1

52.1p

100,000

(d)

Aggregated information

- Aggregated volume
- Price

N/A

(e)

Date of the transaction

21 December 2023

(f)

Place of the transaction

AIMX

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: The Pebble Group



View the original press release on accesswire.com

© 2023 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.